The Insides News- The Insides Neo - fistuloclysis, distal feeding, best, alternative to parenteral nutrition, fistula, ostomy, ileostomy, chyme, enteral, oral nutrition, enteromate, intestinal failure, colon cancer, bowel cancer, gut cancer, ostomy appliance, high output, chyme, dehydration, defunctioned, ileus, lars, microbiome, lower interior resection syndrome, incontinent, incontinence, gut health, reversal surgery
The Insides Company and Palex Sign Distribution Agreement for Spain for Chyme Reinfusion

The Insides Company and Palex Sign Distribution Agreement for Spain for Chyme Reinfusion

November 16, 2023

Press Release

Source:The Insides Company Limited

On:16 November 2023

Organisations:The Insides Company Limited, Palex Medical S.A.U.

Madrid, Spain

The Insides Company, a medical technology company focused on the development and commercialisation of novel chyme reinfusion therapy (CRT) devices for the treatment of intestinal failure, today announces Palex Medical S.A.U. as exclusive partner for Spain following a signing of the distribution agreement.

One of the features that stands out when analysing the Palex Group’s evolution is its dedication to the quest for innovation in products, equipment and systems, and its perseverance in maintaining a high level of quality in all areas of its business activity. Xavier Carbonell, CEO of the Palex Group, points out:“taking The Insides Company in Spain means we can now provide a new innovative solution for these challenging to treat patients to improve their nutritional status and enable them to be at home prior to reconstructive surgery”. Garth Sutherland, CEO of The Insides Company, commented “we have been working with the excellent team at Palex for some time now and we are very pleased to have reached a formal agreement. Palex could see the benefits of chyme reinfusion and with their strong network in clinical nutrition and surgery they are an ideal partner for representing our products in Spain.”

About Type II Intestinal Failure and Chyme Reinfusion Therapy

Type II intestinal failure is the inability of the gut to absorb necessary water, macronutrients, micronutrients, and electrolytes to sufficiently sustain life without intravenous supplementation or replacement. This can be due to malabsorption (small bowel mucosal disease), surgical resection (short bowel syndrome), fistulae, dysmotility, or mechanical obstruction. Under the standard care pathway, patients recovering from colorectal surgery often have an enterostomy created to divert intestinal contents (chyme) away from the surgical site as it heals. The enterostomy is typically left open for 6-12 months, and during this time the chyme that is collected is disposed of, which can result in intestinal failure and other complications. The Insides System is a purpose-built medical device for performing chyme reinfusion therapy. Chyme reinfusion is a practice in the management of patients with high-output enterocutaneous fistulas, and high-output enterostomies.

About Palex

Palex Group is the leading provider of advanced solutions for healthcare professionals in hospital, laboratory, and research settings. Founded in 1955 with a clear innovative vision, it is a leader in supplying equipment to the hospital sector in Southern Europe. With a team of over 800 people, Palex provides healthcare professionals with the most cutting-edge and innovative tools on the market to enable them to perform their best and deliver the best diagnosis and treatment to patients.

About The Insides Company

The Insides Company has commercialised 30 years of clinical experience in gut nutrition into breakthrough medical devices. The Insides Company’s mission is to provide universal access to chyme reinfusion therapy through revolutionary products and education to establish a new standard of care.


The Insides Company

Mark Harvie, Consultant

Telephone:+44 7970 546778

Palex Medical S.A.U.

Raul Torrent, Head of Marketing

Telephone:+34 934 006 532

Choose Your Language

Selecting language below will change the language for